Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G
Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.
You may also be interested in...
The UK’s health technology assessment organization is in favor of funding hybrid closed loop systems for certain people with type 1 diabetes, but only if companies agree to provide such products at more “cost-effective” prices.
Bigfoot Biomedical’s Unity system pairs continuous glucose monitoring with smart insulin pen caps, giving patients recommendations on insulin dosing. Because patient interaction is involved, Bigfoot Biomedical can deliver insulin pump-like results to pump-ineligible type II diabetics.
The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.